抗疱疹病毒感染药物的研究进展  

Research progress on anti-herpesvirus drugs

作　　者：赵雪[1] 唐海 ZHAO Xue;TANG Hai(Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Tasly Academy,Tasly Holding Group.Co.,Ltd.,Tianjin 300410,China)

机构地区：[1]天津中医药大学,天津301617 [2]天士力控股集团有限公司天士力研究院,天津300410

出　　处：《现代药物与临床》2023年第8期2086-2092,共7页Drugs & Clinic

摘　　要：疱疹病毒感染类疾病高发,可形成终生感染,给人类健康和财产安全带来了极大的损失。然而,临床上批准常用的治疗疱疹病毒感染的药物仅几种核苷类似物,这些药物的应用往往还会引发耐药性和不良反应。因而,克服抗疱疹病毒药物存在的问题,探索新型的抗疱疹病毒药物迫在眉睫。总结了临床常用抗疱疹病毒感染药物、靶向病原体的抗疱疹病毒抑制剂和靶向宿主的抗疱疹病毒抑制剂,介绍了联合用药抗病毒新型策略,以期为科研人员在抗疱疹病毒药物方面的研究提供参考。The high incidence of herpesvirus infection can lead to life-long infection,which brings great loss to human health and property safety.Only few nucleoside analog drugs are approved for the treatment of herpesvirus infections,and long-term use of these drugs often leads to drug resistance and adverse action.Overcoming the problems of anti-herpesvirus drugs and exploring new types of anti-herpesvirus drugs is urgent.This article summarizes commonly used anti-herpesvirus infection drugs in clinical practice,anti-herpesvirus inhibitors targeting pathogens,anti-herpesvirus inhibitors targeting hosts,and new strategies for combination therapy of antiviral drugs,hoping to provide reference for researchers in the research of anti-herpesvirus drugs.

关 键 词：抗疱疹病毒感染药物 抑制剂 靶向病原体 靶向宿主 联合用药 

分 类 号：R978.7[医药卫生—药品]